NanoComp

Genetic Immunity's NanoComp medicinal composition platform is the basis of the Company's lead nanomedicine candidates, which consist of nanoparticles containing plasmid DNA of the targeted disease, a polymer and a sugar. The Company's research is focused on the development of new nanomedicines designed to amplify the immune system in treating infectious diseases, allergies, and cancer.

Plasmid DNA is the active pharmaceutical ingredient (API) that determines each nanomedicine candidates' specificity and triggers the immune response necessary to treat the target disease. By modifying DNA-encoded antigens, Genetic Immunity can leverage same NanoComp platform technology for a broad range of indications to induce specific immune responses relevant to specific diseases.